A Study of Nivolumab in Patients With Head and Neck Cancer.

Sponsor: Bristol-Myers Squibb
Study ID: NCT04050761
Status: Completed

Conditions

Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Nivolumab — BIOLOGICAL
Specified dose on Specific Days

Study Details

A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy

Key Dates

First listed: Aug 8, 2019
Start date: Jun 26, 2019
Status verified: Jun 2025
Primary completion: Jul 8, 2024
Completion: Jul 8, 2024

Study Design

Enrollment: 502 participants (actual)

Arms

Arm: Monotherapy
Participants diagnosed with recurrent or metastatic squamous cell carcinoma of the Head and Neck and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of SCCHN.

Primary Outcome Measure

Overall Survival [ Time Frame: 3 Years ]